210 related articles for article (PubMed ID: 12885911)
1. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2.
Ashkar AA; Bauer S; Mitchell WJ; Vieira J; Rosenthal KL
J Virol; 2003 Aug; 77(16):8948-56. PubMed ID: 12885911
[TBL] [Abstract][Full Text] [Related]
2. Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production.
Gill N; Deacon PM; Lichty B; Mossman KL; Ashkar AA
J Virol; 2006 Oct; 80(20):9943-50. PubMed ID: 17005672
[TBL] [Abstract][Full Text] [Related]
3. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract.
Gallichan WS; Woolstencroft RN; Guarasci T; McCluskie MJ; Davis HL; Rosenthal KL
J Immunol; 2001 Mar; 166(5):3451-7. PubMed ID: 11207303
[TBL] [Abstract][Full Text] [Related]
4. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA.
Ashkar AA; Yao XD; Gill N; Sajic D; Patrick AJ; Rosenthal KL
J Infect Dis; 2004 Nov; 190(10):1841-9. PubMed ID: 15499542
[TBL] [Abstract][Full Text] [Related]
5. NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection.
Gill N; Rosenthal KL; Ashkar AA
J Virol; 2005 Apr; 79(7):4470-8. PubMed ID: 15767447
[TBL] [Abstract][Full Text] [Related]
6. Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge.
Sajic D; Ashkar AA; Patrick AJ; McCluskie MJ; Davis HL; Levine KL; Holl R; Rosenthal KL
J Med Virol; 2003 Dec; 71(4):561-8. PubMed ID: 14556270
[TBL] [Abstract][Full Text] [Related]
7. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection.
Harandi AM; Eriksson K; Holmgren J
J Virol; 2003 Jan; 77(2):953-62. PubMed ID: 12502811
[TBL] [Abstract][Full Text] [Related]
8. Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848).
McCluskie MJ; Cartier JL; Patrick AJ; Sajic D; Weeratna RD; Rosenthal KL; Davis HL
Antiviral Res; 2006 Feb; 69(2):77-85. PubMed ID: 16377001
[TBL] [Abstract][Full Text] [Related]
9. Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination.
Bagri P; Anipindi VC; Nguyen PV; Vitali D; Stämpfli MR; Kaushic C
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956763
[TBL] [Abstract][Full Text] [Related]
10. The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challenges.
Harandi AM
J Clin Virol; 2004 Jul; 30(3):207-10. PubMed ID: 15135735
[TBL] [Abstract][Full Text] [Related]
11. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes.
Tengvall S; Lundqvist A; Eisenberg RJ; Cohen GH; Harandi AM
J Virol; 2006 Jun; 80(11):5283-91. PubMed ID: 16699008
[TBL] [Abstract][Full Text] [Related]
12. Importance of myeloid differentiation factor 88 in innate and acquired immune protection against genital herpes infection in mice.
Tengvall S; Harandi AM
J Reprod Immunol; 2008 Jun; 78(1):49-57. PubMed ID: 17945349
[TBL] [Abstract][Full Text] [Related]
13. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2.
Kwant A; Rosenthal KL
Vaccine; 2004 Aug; 22(23-24):3098-104. PubMed ID: 15297061
[TBL] [Abstract][Full Text] [Related]
14. The role of toll-like receptor ligands/agonists in protection against genital HSV-2 infection.
Gill N; Davies EJ; Ashkar AA
Am J Reprod Immunol; 2008 Jan; 59(1):35-43. PubMed ID: 18154594
[TBL] [Abstract][Full Text] [Related]
15. Induction of innate immune responses in the female genital tract: friend or foe of HIV-1 infection?
Firoz Mian M; Ashkar AA
Am J Reprod Immunol; 2011 Mar; 65(3):344-51. PubMed ID: 21223417
[TBL] [Abstract][Full Text] [Related]
16. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.
Jiang JQ; Patrick A; Moss RB; Rosenthal KL
J Virol; 2005 Jan; 79(1):393-400. PubMed ID: 15596832
[TBL] [Abstract][Full Text] [Related]
17. A crucial role for plasmacytoid dendritic cells in antiviral protection by CpG ODN-based vaginal microbicide.
Shen H; Iwasaki A
J Clin Invest; 2006 Aug; 116(8):2237-43. PubMed ID: 16878177
[TBL] [Abstract][Full Text] [Related]
18. CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice.
Tengvall S; Josefsson A; Holmgren J; Harandi AM
J Reprod Immunol; 2005 Dec; 68(1-2):53-69. PubMed ID: 16229896
[TBL] [Abstract][Full Text] [Related]
19. Phosphorothioate-modified oligodeoxynucleotides inhibit human cytomegalovirus replication by blocking virus entry.
Luganini A; Caposio P; Landolfo S; Gribaudo G
Antimicrob Agents Chemother; 2008 Mar; 52(3):1111-20. PubMed ID: 18180342
[TBL] [Abstract][Full Text] [Related]
20. Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection.
Herbst-Kralovetz MM; Pyles RB
J Virol; 2006 Oct; 80(20):9988-97. PubMed ID: 17005677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
